证券简称：信邦制药 证券代码：002390 1 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2023-7-4 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 ■现场参观 □其他 （说明具体形式） 活动参与人员 泰康资产、泰康基金、泰康香港、德邦证券 时间 2023 年 7 月 4 日（周二） 8:30 至 10:30 地点 贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 形式 线下调研 上市公司接待 人员姓名 副总经理、董事会秘书：陈船 一、问答环节 1、医疗服务板块 （1）医疗服务板块总体情况 投资者关系活 公司致力于为居民提供基本以及多元化的优质医疗服 动主要内容介 务，坚持医疗、教学和科研协同发展的办医理念，坚持"一 绍 体化管理、同质化发展"的管理模式，在临床及医技学科实 行首席专家制，在信息化、医保、后勤等保障体系实行集团 中心化管理，实现了专家、医患及设备等资源共享。公司现 证券简称：信邦制药 证券代码：002390 拥有肿瘤医院、白云医院、乌当医院、仁怀新朝阳医院等 6 家医疗机构，拥有床位数 5,000 余张。 肿瘤医院 ...

证券简称：信邦制药 证券代码：002390 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2023-6-2 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 ■现场参观 □其他 （说明具体形式） 活动参与人员 平安证券、平安银行、招商资管、春晖基金 时间 2023 年 6 月 2 日（周五） 14:00 至 16:00 地点 贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 形式 线下调研 上市公司接待 人员姓名 副总经理、董事会秘书：陈船 一、公司基本情况介绍 信邦制药成立于 1995 年，2000 年进行了股份制改制， 于 2010 年在深交所挂牌上市，2014 年公司完成了与科开医 药的重大资产重组，2021 年完成非公开发行。历经不断发展 投资者关系活 和创新，公司已成为集医疗服务、医药流通和医药制造的医 动主要内容介 疗健康全产业链集团，形成了以医疗服务为核心，医药流通、 绍 医药制造协同发展的创新发展模式，构建了"医疗服务+" 平台运营模式。2022 年，公司资产总额 97.93 亿元，实现营 业收入 63.50 亿元，归属于母公 ...

证券简称：信邦制药 证券代码：002390 编号：2023-5-25 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系 活动类别 □新闻发布会 □路演活动 ■现场参观 □其他 （说明具体形式） 天风证券、民生证券、德睿基金、机缘投资、南土资产、鼎 活动参与人员 锋资产、东吴资管 时间 2023 年 5 月 25 日（周四） 9:00 至 11:30 贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑、贵州 地点 医科大学附属肿瘤医院有限公司 形式 线下调研 上市公司接待 人员姓名 副总经理、董事会秘书：陈船 一、问答环节 1、医疗服务板块 2022 年度运营情况以及未来规划？ （1）整体运营情况及未来规划 投资者关系活 动主要内容介 2022 年度，公司医疗服务板块实现营业收入18.61 亿元， 绍 同比下降 10.18%；毛利率为 9.58%，同比下降 3.16%。全年 门急诊 108 万人次、出入院共 20 万人次、放疗 8.3 万人次、 手术 3.22 万台次。 贵州信邦制药股份有限公司 投资者关系活动记录表 1 证券简称：信邦制药 证券代码：002390 在医疗服务板块，公司未来 ...

证券简称：信邦制药 证券代码：002390 贵州信邦制药股份有限公司 具体计划？ 投资者关系活动记录表 编号：2023-5-17 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 ■业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | 现场参观 | | | □其他 （说明具体形式） | | 活动参与人员 | 1、董事长：安吉 | | | 2、独立董事：邱刚 | | | 3、副总经理、财务总监：肖娅筠 | | | 4、副总经理、董事会秘书：陈船 | | | 5、通过全景网"投资者关系互动平台"参与 2022 年度贵州 | | | 辖区上市公司业绩说明会暨投资者集体招待日活动的投资 | | | 者。 | | 时间 | 2023 年 5 月 17 日（周三） 15:30 至 17:30 | | 地点 | 全景网"投资者关系互动平台"（https://ir.p5w.net） | | 形式 | 线上问答 | | | 公司于 2023 年 5 月 17 日参与 2022 年度贵州辖区上市 | | | 公司业绩说明会暨投资者集体招待日活动，公司管理层针 ...

证券代码：002390 证券简称：信邦制药 公告编号：2023-020 出席本次活动人员：董事长安吉女士，独立董事邱刚先生，副 总经理、财务总监肖娅筠女士，副总经理、董事会秘书陈船女士。 参 与 方 式 ： 投 资 者 可 于 业 绩 说 明 会 召 开 时 间 登 录 http://rs.p5w.net 进入专区页面参与交流。 二、投资者问题提前征集 贵州信邦制药股份有限公司 关于参加2022年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年 度报告》，为加强与投资者的交流互动，便于投资者进一步了解公 司 2022 年度经营情况及其他关切问题，公司将参加在贵州证监局指 导下，贵州证券业协会联合深圳市全景网络有限公司举办的"2022 年度贵州辖区上市公司业绩说明会暨投资者集体接待日活动"，具 体安排如下： 一、业绩说明会的安排 召开时间：2023 年 ...

证券代码：002390 证券简称：信邦制药 公告编号：2023-020 贵州信邦制药股份有限公司 关于参加2022年度贵州辖区上市公司业绩说明会暨 投资者集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）已于 2023 年 4 月 18 日在巨潮资讯网（www.cninfo.com.cn）披露了《2022 年年 度报告》，为加强与投资者的交流互动，便于投资者进一步了解公 司 2022 年度经营情况及其他关切问题，公司将参加在贵州证监局指 导下，贵州证券业协会联合深圳市全景网络有限公司举办的"2022 年度贵州辖区上市公司业绩说明会暨投资者集体接待日活动"，具 体安排如下： 一、业绩说明会的安排 召开时间：2023 年 5 月 17 日 15:30-17:30。 召开方式：网络远程方式。 出席本次活动人员：董事长安吉女士，独立董事邱刚先生，副 总经理、财务总监肖娅筠女士，副总经理、董事会秘书陈船女士。 参 与 方 式 ： 投 资 者 可 于 业 绩 说 明 会 召 开 时 间 登 录 http:// ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,605,127,137.43, representing a 1.70% increase compared to ¥1,578,346,374.84 in the same period last year[2] - Net profit attributable to shareholders decreased by 27.94% to ¥52,944,770.89 from ¥73,477,230.21 year-on-year[2] - Net profit for Q1 2023 was CNY 62,648,520.70, a decrease from CNY 79,535,695.47 in Q1 2022, reflecting a decline of approximately 21.2%[16] - The total comprehensive income for Q1 2023 was ¥62,648,520.70, down from ¥79,535,695.47 in the same period last year, reflecting a decline of approximately 21%[17] - The basic and diluted earnings per share for Q1 2023 were both ¥0.03, compared to ¥0.04 in Q1 2022, indicating a 25% decrease[17] Cash Flow - The net cash flow from operating activities significantly dropped by 98.40%, amounting to ¥2,178,740.78 compared to ¥136,064,884.82 in the previous year[5] - Cash received from sales of goods and services in Q1 2023 was ¥1,465,643,505.99, a decline of about 7.4% from ¥1,582,853,471.06 in Q1 2022[20] - The net cash flow from operating activities for Q1 2023 was ¥2,178,740.78, significantly lower than ¥136,064,884.82 in Q1 2022[20] - The net cash flow from investing activities in Q1 2023 was -¥48,209,725.41, compared to -¥72,216,888.53 in Q1 2022, showing an improvement in cash outflow[21] - The net cash flow from financing activities for Q1 2023 was ¥60,850,727.62, contrasting with a negative cash flow of -¥9,290,728.22 in Q1 2022[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥9,889,925,341.80, a 0.99% increase from ¥9,793,091,573.35 at the end of the previous year[2] - Total assets as of March 31, 2023, amounted to CNY 9,889,925,341.80, compared to CNY 9,793,091,573.35 at the beginning of the year, showing an increase of about 1.0%[12] - Total liabilities as of March 31, 2023, were CNY 2,763,288,937.98, slightly up from CNY 2,728,042,922.48 at the start of the year, representing an increase of approximately 1.3%[13] Shareholder Information - The total equity attributable to shareholders increased by 0.78% to ¥6,861,396,417.39 from ¥6,808,451,646.50 at the end of the previous year[2] - The company had a total of 82,166 common shareholders at the end of the reporting period[7] - The company's total equity as of March 31, 2023, was CNY 7,126,636,403.82, compared to CNY 7,065,048,650.87 at the beginning of the year, reflecting a growth of about 0.9%[13] Research and Development - Research and development expenses surged by 398.74% to ¥691,393.55, indicating increased investment in R&D projects[5] - Research and development expenses for Q1 2023 were CNY 691,393.55, significantly higher than CNY 138,626.92 in Q1 2022, marking an increase of approximately 397.5%[16] Other Income - The company reported a significant increase in other operating income, which rose by 447.32% to ¥1,217,905.71 compared to ¥222,522.05 in the previous year[5] Equity and Returns - The weighted average return on equity decreased by 0.33 percentage points to 0.77% from 1.10% year-on-year[2]

Business Focus and Structure - The company reported a significant change in its main business focus from pharmaceutical manufacturing to medical services, pharmaceutical distribution, and pharmaceutical manufacturing since March 2014[32]. - The company’s major shareholder has changed from Zhang Guanfeng to Harbin Yuxi Venture Capital Co., Ltd. in August 2017, and then to Guizhou Jinyu Industrial Investment Partnership (Limited Partnership) in June 2021[32]. - The company has established multiple subsidiaries, including Guizhou Kexin Pharmaceutical Co., Ltd. and Guizhou Tongde Pharmaceutical Co., Ltd., enhancing its market presence[13]. - The company operates seven medical institutions, including the only Grade A tumor specialty hospital in Guizhou Province[47]. - The company has established a comprehensive healthcare industry chain, integrating medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing[51]. Financial Performance - The financial report for the year 2022 was confirmed to be true, accurate, and complete by the responsible persons including the company leader and accounting supervisor[2]. - The annual report includes a comprehensive analysis of the company's financial indicators, which are crucial for assessing performance[29]. - The company's operating revenue for 2022 was ¥6,350,025,827.03, a decrease of 1.88% compared to ¥6,471,866,334.96 in 2021[34]. - The net profit attributable to shareholders for 2022 was ¥224,479,086.87, down 17.73% from ¥272,869,187.71 in 2021[34]. - The net cash flow from operating activities increased by 29.00% to ¥590,796,585.74 in 2022, compared to ¥457,971,988.24 in 2021[34]. - Basic and diluted earnings per share for 2022 were both ¥0.12, representing a decrease of 20.00% from ¥0.15 in 2021[35]. - The weighted average return on equity for 2022 was 3.36%, down 1.37 percentage points from 4.73% in 2021[35]. - Total assets at the end of 2022 were ¥9,793,091,573.35, an increase of 1.71% from ¥9,628,645,372.98 at the end of 2021[35]. - Net assets attributable to shareholders at the end of 2022 were ¥6,808,451,646.50, up 2.85% from ¥6,619,762,004.21 at the end of 2021[35]. Market Trends and Opportunities - The pharmaceutical distribution market in China continues to grow, driven by increasing healthcare demands and improved medical insurance systems[48]. - The aging population in China is expected to drive increased demand for healthcare services and pharmaceutical products, presenting growth opportunities for the company[66]. - The overall healthcare expenditure in China reached CNY 7.56 trillion in 2021, accounting for 6.58% of GDP, indicating a growing market for pharmaceutical products[64]. - The company aims to expand its market presence by leveraging its strengths in product development and distribution channels[64]. - The company is exploring digital transformation and innovative service models to improve supply chain logistics and customer service[70]. Revenue Breakdown - Revenue from pharmaceutical distribution was ¥5,280,248,211.04, accounting for 66.51% of total revenue, down 1.53% from the previous year[95]. - Revenue from medical services decreased by 10.18% to ¥1,860,172,021.49, representing 23.43% of total revenue[95]. - Pharmaceutical manufacturing revenue increased by 12.23% to ¥790,255,875.26, making up 9.95% of total revenue[95]. - The total operating revenue for the company in Q4 2022 was approximately CNY 1.66 billion, showing a slight increase compared to previous quarters[60]. Operational Efficiency and Management - The company has implemented a centralized management model to enhance resource sharing and operational efficiency across its medical services[76]. - The company has established a platform operating model that integrates medical services, pharmaceutical distribution, and manufacturing, enhancing its competitive edge[82]. - The company is focusing on expanding its medical services to address the growing demand for healthcare resources in underserved areas[97]. - The company has developed a modern pharmaceutical logistics distribution system that not only supports its own operations but also provides third-party logistics services[117]. Research and Development - The company has been focusing on the development of new products and technologies to enhance its market position in the pharmaceutical industry[64]. - The company aims to enhance the quality of traditional Chinese medicine (TCM) and has established a comprehensive quality control system for TCM materials[73]. - The company has received approval for over 40 research projects in 2022, including 1 national-level project and 31 provincial-level projects[140]. - The company is focusing on research related to cancer treatment, particularly in improving chemotherapy resistance in pancreatic cancer[173]. Challenges and Risks - The company faces risks related to rising costs, including raw material prices and labor costs, which may impact future profitability[200]. - The company is exposed to financial risks due to its extensive operations in medical services and pharmaceutical distribution, requiring significant working capital[200]. - The company is adapting to industry changes driven by policies such as "two-invoice system" and "volume-based procurement," which are reshaping the pharmaceutical landscape[80]. Strategic Initiatives - The company aims to build a high-tech medical service group, focusing on medical services, pharmaceutical distribution, and traditional Chinese medicine manufacturing[199]. - The company is pursuing both organic growth and strategic acquisitions to ensure sustainable and stable development, creating more value for shareholders[119]. - The company has initiated several projects under its five-year technology innovation plan, including the application for 8 invention patents and 1 utility model patent[141].

证券代码：002390 证券简称：信邦制药 贵州信邦制药股份有限公司 投资者关系活动记录表 编号：2015-09-23 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | | 中国银河证券股份有限公司：全铭 | | 人员姓名 | | 易方达基金管理有限公司：王俊杰 | | | | 华润元大基金管理有限公司：张磊 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 深圳尊道投资有限公司：张伟生 | | | | | 广东小禹投资管理有限公司：何结领 | | | | 北京亚宝投资管理有限公司：郭常平 | | | 东莞证券股份有限公司 | : 陈毅 | | | | 上海之上资产管理有限公司：周坤 | | ...